U.S. Government to Fund New Research on Psychedelic Drug Ibogaine for PTSD

Federal officials have announced new funding, up to $4.9 million, to explore the medical potential of ibogaine, a psychedelic drug, for treating post-traumatic stress disorder (PTSD). This initiative, championed by veterans and lawmakers, aims to lay the groundwork for the first U.S. studies of ibogaine for PTSD, a condition linked to higher rates of suicide and substance abuse among veterans. Ibogaine, currently illegal in the U.S., is known for causing intense hallucinations and other side effects, but advocates believe it holds promise for intractable conditions.